Leo Pharma Positioned for IPO in 2026
Leo Pharma is preparing for an initial public offering (IPO) in 2026, as stated by CEO Christophe Bourdon. Despite this, he remains cautious about revealing any specific dates regarding the IPO timing.
Leadership and Expertise at Leo Pharma
- Senior Scientist in Translational Pharmacology
- Operational Excellence Specialist - Pharmaceutical Production Director
- Head of Regulatory Operations
- Lead Quality Assurance Professional – Combination Products
- Global Channel Partner Director (APAC), Celvivo
- BRIDGE Translational Excellence Programme Senior Director
- IT Infrastructure & Operations Senior Director
- Regulatory Intelligence Specialist
- Postdoctoral Scientist specializing in Machine Learning for Antibody Discovery and Design
- Senior Medical Information Manager
“We have a compelling case,” said CEO Christophe Bourdon regarding the upcoming IPO.
Author’s summary: Leo Pharma is strategically positioned for a 2026 IPO, supported by a strong leadership team and specialized expertise, while maintaining discretion on exact timing.